Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic targeting ...

Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders should be happy to see the share price up 11% in the ...

Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report). The ...

Fmr LLC cut its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 10.9% in the third quarter, ...

Charles Schwab Investment Management Inc. increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – ...

The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since it hit its lowest value of the past year. On Oct. 10, ...

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $23.11 which represents a decrease of $-2.96 or -11.35% from the prior close of $26.07. The stock opened at $26.15 and ...

Q4 2024 Earnings Call Transcript November 26, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery ...

On Friday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $26.03 which represents a decrease of $-0.12 or -0.46% from the prior close of $26.15. The stock opened at $26.15 ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 36th Annual ...